# BPC-157: Research Overview — Cowboy Up Peptide > A literature summary of BPC-157 (Body Protection Compound 157): angiogenesis mechanism, rodent healing studies, pharmacokinetics, and regulatory status. A digest, not medical advice. Body Protection Compound 157 — a stable gastric pentadecapeptide whose repair effects, in animals, trace most consistently to the growth of new blood vessels. ## The short version BPC-157 stands for **Body Protection Compound 157**. It is a synthetic peptide fifteen amino acids long, derived from part of a protective protein found in human gastric juice. In animal studies — overwhelmingly in rats — it appears to accelerate healing across several tissue types: tendons, the gut lining, muscle, bone and nerve [5]. The most consistent explanation researchers put forward is that it prompts the body to grow new blood vessels into an injury site, bringing the oxygen and nutrients that repair demands [4]. Here is the honest accounting. Almost all of this evidence is in animals. As of 2025, only three small human pilot studies of BPC-157 exist, and no large, rigorous controlled trials have been completed [2]. BPC-157 is not an approved drug anywhere. It is prohibited in sport. Popular claims about weight loss, muscle gain or testosterone are not supported by the published literature [2]. This page summarizes what was studied; it does not advise on use and lists no human dose. ## What it is BPC-157 is a *stable gastric pentadecapeptide* — "pentadecapeptide" means a peptide of fifteen amino acids, and "stable gastric" signals both that the sequence originates from a cytoprotective protein in gastric juice and that it resists breakdown in stomach acid. Its amino-acid sequence is `Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val`; molecular formula C62H98N16O22. It is also catalogued in the literature under the research designations PL 14736, PLD-116, PL-10, and Bepecin. BPC-157 is a synthetic research peptide — not extracted from a natural source, not a hormone, and not an approved drug or dietary supplement. ## How it works The best-documented mechanism is *angiogenesis* — the formation of new blood vessels into tissue that needs repair. A 2017 study spanning a chick chorioallantoic membrane model, rat hindlimb ischemia, and human vascular endothelial cells showed that BPC-157 up-regulated the expression of VEGFR2 (a key vessel-growth receptor) and promoted its internalization, activating the downstream VEGFR2-Akt-eNOS (nitric-oxide) pathway; blocking that internalization blocked the effect [4]. In plain terms: BPC-157 appears to make blood-vessel cells more responsive to the body's own "grow new vessels" signal, and it accelerated blood-flow recovery in an ischemic muscle model in the same experiments [4]. Beyond angiogenesis, the literature describes additional reported routes — FAK-paxillin cell-migration signaling, sensitization of the growth-hormone receptor in tendon fibroblasts, and modulation of the nitric-oxide system and several neurotransmitter pathways [4]. The picture is of a peptide that nudges several repair-relevant processes at once rather than hitting a single clean target. ## What the research shows *Foundational cytoprotection.* The compound's name is rooted in gut biology. In Wistar rats, BPC-157 reduced gastric ulcer area and accelerated ulcer healing, with intramuscular delivery outperforming intragastric, and ulcer-formation inhibition ratios of roughly 46-66% at higher doses [5]. *Pharmacokinetics.* The first formal PK/ADME characterization, in rats and beagle dogs, found linear pharmacokinetics, a very short elimination half-life under 30 minutes, modest intramuscular bioavailability (approximately 14-19% in rats and 45-51% in dogs), and rapid breakdown into small peptide fragments that re-enter normal amino-acid metabolism [3]. A short half-life means the intact peptide clears the bloodstream quickly after dosing. *Angiogenesis in vivo.* The 2017 VEGFR2 study demonstrated increased vessel density in both chick and rat models and accelerated blood-flow recovery in ischemic muscle — with the mechanism traced to VEGFR2 internalization and downstream Akt-eNOS activation [4]. *Human evidence.* It is genuinely small. A 2025 first-in-human intravenous safety pilot gave BPC-157 up to 20 mg to two healthy adults; it was well tolerated, with no observed adverse events and no measurable changes in cardiac, hepatic, renal, thyroid or glucose biomarkers [1]. Two people in a safety pilot is not efficacy evidence. A 2025 narrative review concludes that only three pilot studies have examined BPC-157 in humans, that rigorous large-scale trials are lacking, and that the peptide should be treated as investigational [2]. ## Reported effects, cautions & safety The safety picture within the tiny human dataset and the animal work is reassuring as far as it reaches — but "as far as it reaches" is the operative phrase. The absence of long-term, large-sample human safety data means the real-world safety profile is genuinely unknown [2]. Several cautions follow directly from the peer-reviewed record: - *Overwhelmingly preclinical evidence.* Most of what is reported comes from rodents, and a significant portion of the foundational literature originates from a single research group — a replication gap that newer authors explicitly flag [2]. - *Unregulated supply.* BPC-157 is not an approved drug anywhere and is widely distributed through non-regulated channels, meaning product identity, purity and actual dose are unverified outside formal studies. - *Banned in sport.* WADA prohibits BPC-157 at all times under the S0 non-approved-substances category — a direct concern for competitive athletes. - *Unsubstantiated claims.* Common online assertions — weight loss, muscle building, testosterone increases — are not supported by the published evidence and should be treated skeptically [2]. - *Three human pilots.* The safety reassurance from animal and pilot data is real but narrow; without large, controlled human trials, the benefit-risk profile in people remains open. ## Where it fits in recovery research BPC-157 is the lead compound on this desk, and the more broadly studied of the two. Its animal record spans tendon, gut, muscle and nerve repair, unified by an angiogenesis-forward story — new vessels as the common engine of repair across tissue types. Its human file is three small pilots [2]. Alongside [KPV](/kpv), which approaches healing from the inflammation side, BPC-157 represents the supply-and-structure angle: bringing blood vessels in, not quieting signals down. See the [comparison page](/compare) for how they line up. ![BPC-157 peptide research illustration — fine filament networks and healing matrices in cold gunmetal cyan](/images/bpc-157.webp) --- A literature digest on repair-peptide research — study findings in plain language, citations intact, nothing for sale and no dosing advice.